JP2016529484A5 - - Google Patents

Download PDF

Info

Publication number
JP2016529484A5
JP2016529484A5 JP2016521841A JP2016521841A JP2016529484A5 JP 2016529484 A5 JP2016529484 A5 JP 2016529484A5 JP 2016521841 A JP2016521841 A JP 2016521841A JP 2016521841 A JP2016521841 A JP 2016521841A JP 2016529484 A5 JP2016529484 A5 JP 2016529484A5
Authority
JP
Japan
Prior art keywords
seq
antibody
fra
therapeutic agent
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016521841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529484A (ja
JP6383787B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/043402 external-priority patent/WO2014205342A2/en
Publication of JP2016529484A publication Critical patent/JP2016529484A/ja
Publication of JP2016529484A5 publication Critical patent/JP2016529484A5/ja
Application granted granted Critical
Publication of JP6383787B2 publication Critical patent/JP6383787B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016521841A 2013-06-20 2014-06-20 卵巣癌の治療方法 Expired - Fee Related JP6383787B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361837543P 2013-06-20 2013-06-20
US61/837,543 2013-06-20
PCT/US2014/043402 WO2014205342A2 (en) 2013-06-20 2014-06-20 Methods for treatment of ovarian cancer

Publications (3)

Publication Number Publication Date
JP2016529484A JP2016529484A (ja) 2016-09-23
JP2016529484A5 true JP2016529484A5 (enExample) 2017-08-03
JP6383787B2 JP6383787B2 (ja) 2018-08-29

Family

ID=52105530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016521841A Expired - Fee Related JP6383787B2 (ja) 2013-06-20 2014-06-20 卵巣癌の治療方法

Country Status (8)

Country Link
US (2) US20160311921A1 (enExample)
EP (1) EP3011013A4 (enExample)
JP (1) JP6383787B2 (enExample)
AU (1) AU2014284212B2 (enExample)
BR (1) BR112015031950A2 (enExample)
CA (1) CA2914237A1 (enExample)
MX (1) MX2015017950A (enExample)
WO (1) WO2014205342A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006241099B2 (en) * 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
KR102700777B1 (ko) * 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
EP3710482A4 (en) 2017-11-14 2021-08-18 University Of Virginia Patent Foundation COMPOSITIONS AND METHODS OF MANUFACTURING AND USING BISPECIFIC ANTIBODIES
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
CN114828895A (zh) * 2019-12-23 2022-07-29 卫材R&D管理有限公司 制备基于艾日布林的抗体-药物缀合物的方法
CN117741149A (zh) * 2024-02-19 2024-03-22 卡秋(江苏)生物科技有限公司 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851332A (en) 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
US6351666B1 (en) 1998-02-27 2002-02-26 Biofield Corp. Method and apparatus for sensing and processing biopotentials
EP1016276A1 (en) 1998-07-16 2000-07-05 Imageid Ltd. Image identification and delivery system
JP3952599B2 (ja) 1998-07-16 2007-08-01 松下電器産業株式会社 映像表示装置および映像表示方法
US6694090B1 (en) 1998-07-20 2004-02-17 Thomson Licensing S.A. Method and apparatus for dynamically overriding a ratings limit during playback of a digital program
ES2169612T3 (es) 1998-07-21 2002-07-01 Koninkl Philips Electronics Nv Sistema para la transmision de datos desde un portador de datos a una estacion por medio de al menos otra señal portadora auxiliar.
IT1303624B1 (it) 1998-07-22 2000-11-15 Techint Spa Dispositivo per elettrodeposizione a cella circonferenziale a flussidifferenziati.
DE19833226C1 (de) 1998-07-23 2000-04-20 Steuler Industriewerke Gmbh Niederschlagsrohrbündel für Naßelektrofilter
DE19833340A1 (de) 1998-07-24 2000-02-10 Karlsruhe Forschzent Wurmförmiger Arbeitsmechanismus
JP2002521177A (ja) 1998-07-24 2002-07-16 ザ、プロクター、エンド、ギャンブル、カンパニー 改良浸漬チューブ付注出ポンプを備える内袋型容器
CA2338369C (en) 1998-07-24 2005-04-05 Yoshino Kogyosho Co., Ltd. Vessel equipped with a manual pump
IT1301872B1 (it) 1998-07-24 2000-07-07 Abb Adda S P A Dispositivo di comando e controllo di interruttori di alta e mediatensione
WO2000005435A2 (en) 1998-07-24 2000-02-03 Ce Resources Pte Ltd. Array electrophoretic apparatus
WO2003094929A2 (en) * 2002-05-06 2003-11-20 University Of Utah Research Foundation Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP1910821B1 (en) * 2005-06-24 2013-02-20 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
US8986650B2 (en) * 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
RU2009127775A (ru) * 2006-12-20 2013-11-10 Джей-Си ХЕЛТ КЭА ЛТД. Способ введения пегилированного липосомального доксорубицина
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
WO2012061759A2 (en) * 2010-11-05 2012-05-10 Morphotek Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
CN107011439B (zh) 2011-07-15 2020-11-10 卫材R&D管理有限公司 抗叶酸受体α抗体及其应用
PL2890717T3 (pl) * 2012-08-31 2020-08-10 Immunogen, Inc. Testy i zestawy diagnostyczne do wykrywania receptora folianu

Similar Documents

Publication Publication Date Title
AU2011281700B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
JP2016529484A5 (enExample)
US20130121999A1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
KR20140094594A (ko) 유방암 치료를 위한 베바시주맙 병용 치료에 대한 혈장 바이오마커
Kim et al. Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review
WO2017210624A1 (en) Anti-pd-1 antibody for use in a method of treating a tumor
WO2014205342A4 (en) Methods for treatment of ovarian cancer
RU2017136863A (ru) Способы лечения рака легкого
Gao et al. CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer
JP2018516244A5 (enExample)
Kim et al. Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
Zhou et al. Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer
EP3216460B1 (en) Antigen polypeptide for detecting plasma immunological marker-vegfr1 autoantibody and use thereof
Wang et al. Fork head box M1 regulates vascular endothelial growth factor-A expression to promote the angiogenesis and tumor cell growth of gallbladder cancer
Sun et al. Expression of annexin A5 in serum and tumor tissue of patients with colon cancer and its clinical significance
WO2021229293A2 (en) Endogenous retroviruses for the detection, diagnosis, and prognosis of cancer
US20230190752A1 (en) Compositions and methods for predicting therapeutic outcome
CN121175569A (zh) Pro-c5测定
RU2014110270A (ru) Способ прогнозирования риска гипертензии, связанной с антиангиогенной терапией
HK1181459B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
HK1184854B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer